LY-2584702 (hydrochloride)
LY-2584702 (hydrochloride) Basic information
- Product Name:
- LY-2584702 (hydrochloride)
- Synonyms:
-
- LY2584702 HCl
- LY-2584702 (hydrochloride)
- 4-[4-[4-[4-Fluoro-3-(trifluoromethyl)phenyl]-1-methyl-1H-imidazol-2-yl]-1-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidine hydrochloride (1:1)
- LY-2584702 hydrochloride (LY2584702)
- LY 2584702 hydrochloride,LY2584702 hydrochloride
- CAS:
- 1082948-81-9
- MF:
- C21H20ClF4N7
- MW:
- 481.88
- Mol File:
- 1082948-81-9.mol
LY-2584702 (hydrochloride) Chemical Properties
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
LY-2584702 (hydrochloride) Usage And Synthesis
Uses
LY-2584702 hydrochloride is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM.
in vivo
LY-2584702 demonstrates significant single-agent efficacy in both U87MG glioblastoma and HCT116 colon carcinoma xenograft models at two dose levels of 2.5 mg/kg twice daily (BID) and 12.5 mg/kg BID. LY-2584702 demonstrates statistically significant tumour growth reduction at TMED50 (threshold minimum effective dose 50%) (2.3 mg/kg) and TMED90 (10 mg/kg) in the HCT116 colon carcinoma xenograft model[1]. To examine the role of S6K in vivo, EOMA cells expressing shAkt3 are implanted in nu/nu mice, then treated for 14 days with LY-2584702 or Rapamycin. Analysis of tumors removed after 14 days shows that LY-2584702 inhibits S6 phosphorylation almost as effectively as Rapamycin. Loss of Akt3 increases tumor growth as compared with pLKO. LY-2584702 treatment alone does not significantly affect the growth of pLKO tumors. However, LY-2584702 significantly reduces the growth of tumors with shAkt3[2].
IC 50
p70S6K: 4 nM (IC50)
References
[1] Tolcher A, et al. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumors. Eur J Cancer. 2014 Mar;50(5):867-75. DOI:10.1016/j.ejca.2013.11.039
[2] Phung TL, et al. Akt1 and akt3 exert opposing roles in the regulation of vascular tumor growth. Cancer Res. 2015 Jan 1;75(1):40-50. DOI:10.1158/0008-5472.CAN-13-2961
[3] Chen B, et al. Hyperphosphorylation of RPS6KB1, rather than overexpression, predicts worse prognosis in non-small cell lung cancer patients. PLoS One. 2017 Aug 9;12(8):e0182891. DOI:10.1371/journal.pone.0182891
LY-2584702 (hydrochloride)Supplier
- Tel
- sales@boylechem.com
- Tel
- 028-81700200 18116577057
- 3003855609@qq.com
- Tel
- 0512-87182056 18013166090
- lingling.qi@yacoo.com.cn
- Tel
- +86-21-5821 5861
- sales@letopharm.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com